News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
333,414 Results
Type
Article (20042)
Company Profile (128)
Press Release (313244)
Multimedia
Podcasts (70)
Webinars (11)
Section
Business (105403)
Career Advice (879)
Deals (18536)
Drug Delivery (97)
Drug Development (50798)
Employer Resources (79)
FDA (7698)
Job Trends (7746)
News (185933)
Policy (17345)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (737)
Accelerated approval (3)
Adcomms (17)
Allergies (40)
Alliances (27843)
ALS (55)
Alzheimer's disease (639)
Antibody-drug conjugate (ADC) (89)
Approvals (7707)
Artificial intelligence (138)
Autoimmune disease (15)
Automation (4)
Bankruptcy (177)
Best Places to Work (5553)
BIOSECURE Act (13)
Biosimilars (95)
Biotechnology (57)
Bladder cancer (31)
Brain cancer (19)
Breast cancer (106)
Cancer (1034)
Cardiovascular disease (111)
Career advice (712)
Career pathing (20)
CAR-T (55)
Cell therapy (150)
Cervical cancer (5)
Clinical research (42672)
Collaboration (454)
Compensation (165)
Complete response letters (23)
COVID-19 (1099)
CRISPR (22)
C-suite (146)
Cystic fibrosis (58)
Data (1105)
Decentralized trials (2)
Denatured (18)
Depression (24)
Diabetes (138)
Diagnostics (1809)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (21)
Drug discovery (80)
Drug pricing (108)
Drug shortages (30)
Duchenne muscular dystrophy (59)
Earnings (39015)
Editorial (31)
Employer branding (10)
Employer resources (73)
Events (48557)
Executive appointments (432)
FDA (8270)
Featured Employer (23)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (308)
Gene editing (47)
Generative AI (18)
Gene therapy (144)
GLP-1 (589)
Government (1846)
Grass and pollen (2)
Guidances (18)
Healthcare (5904)
Huntington's disease (13)
IgA nephropathy (20)
Immunology and inflammation (82)
Indications (17)
Infectious disease (1180)
Inflammatory bowel disease (82)
Inflation Reduction Act (8)
Influenza (25)
Intellectual property (55)
Interviews (116)
IPO (7370)
IRA (45)
Job creations (2432)
Job search strategy (648)
Kidney cancer (7)
Labor market (21)
Layoffs (276)
Leadership (14)
Legal (4120)
Liver cancer (31)
Lung cancer (156)
Lymphoma (85)
Machine learning (2)
Management (30)
Manufacturing (197)
MASH (49)
Medical device (1963)
Medtech (1966)
Mergers & acquisitions (11418)
Metabolic disorders (492)
Multiple sclerosis (48)
NASH (20)
Neurodegenerative disease (52)
Neuropsychiatric disorders (21)
Neuroscience (953)
NextGen: Class of 2025 (2358)
Non-profit (906)
Northern California (1060)
Now hiring (20)
Obesity (309)
Opinion (190)
Ovarian cancer (33)
Pain (65)
Pancreatic cancer (35)
Parkinson's disease (86)
Partnered (11)
Patents (139)
Patient recruitment (45)
Peanut (16)
People (33443)
Pharmaceutical (74)
Pharmacy benefit managers (21)
Phase I (13360)
Phase II (18048)
Phase III (14505)
Pipeline (705)
Policy (115)
Postmarket research (1619)
Preclinical (4657)
Press Release (29)
Prostate cancer (59)
Psychedelics (16)
Radiopharmaceuticals (161)
Rare diseases (244)
Real estate (3174)
Recruiting (29)
Regulatory (12524)
Reports (22)
Research institute (819)
Resumes & cover letters (138)
Rett syndrome (1)
RNA editing (2)
RSV (25)
Schizophrenia (59)
Series A (57)
Series B (32)
Service/supplier (7)
Sickle cell disease (36)
Southern California (1017)
Special edition (15)
Spinal muscular atrophy (113)
Sponsored (12)
Startups (2009)
State (2)
Stomach cancer (9)
Supply chain (51)
Tariffs (21)
The Weekly (50)
United States (9974)
Vaccines (268)
Venture capitalists (27)
Weight loss (239)
Women's health (14)
Worklife (7)
Date
Today (55)
Last 7 days (242)
Last 30 days (1248)
Last 365 days (16840)
2025 (4645)
2024 (17679)
2023 (19648)
2022 (25867)
2021 (26639)
2020 (24871)
2019 (20058)
2018 (15588)
2017 (17254)
2016 (16202)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (409)
Alabama (23)
Alaska (1)
Arizona (64)
Arkansas (8)
Asia (24875)
Australia (3219)
California (2479)
Canada (1091)
China (319)
Colorado (95)
Connecticut (103)
Delaware (69)
Europe (51372)
Florida (433)
Georgia (54)
Idaho (16)
Illinois (243)
India (19)
Indiana (171)
Iowa (3)
Japan (115)
Kansas (62)
Kentucky (17)
Louisiana (2)
Maine (4)
Maryland (360)
Massachusetts (2097)
Michigan (48)
Minnesota (136)
Mississippi (1)
Missouri (27)
Montana (10)
Nebraska (11)
Nevada (16)
New Hampshire (8)
New Jersey (1013)
New Mexico (21)
New York (726)
North Carolina (492)
North Dakota (2)
Northern California (1060)
Ohio (81)
Oklahoma (5)
Oregon (21)
Pennsylvania (590)
Puerto Rico (11)
Rhode Island (16)
South America (607)
South Carolina (3)
Southern California (1017)
Tennessee (38)
Texas (327)
Utah (54)
Virginia (82)
Washington D.C. (43)
Washington State (214)
Wisconsin (20)
333,414 Results for "biohaven pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neuropsychiatric disorders
Biohaven Disappoints Again, This Time in Phase II/III Bipolar Mania Trial
Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its protein degrader candidate that investors found underwhelming.
March 4, 2025
·
2 min read
·
Tristan Manalac
Legal
Pfizer Settles Biohaven Kickback Suit for Nearly $60M
From March 2020 through September 2022, Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe its migraine therapy Nurtec ODT, according to the Department of Justice.
January 27, 2025
·
2 min read
·
Tristan Manalac
Antibody-drug conjugates
Merus and Biohaven Strike New ADC Collaboration
On the heels of an FDA approval for its monoclonal antibody Bizengri, Merus will generate three novel cancer-targeting antibodies that it will pass over to Biohaven to link into antibody drug-conjugates.
January 13, 2025
·
1 min read
·
Dan Samorodnitsky
Neurodegenerative disease
Biohaven Drug Misses in Phase III for SMA, Will Be Tested in Obesity
While taldefgrobep alfa failed to show improved motor function in spinal muscular atrophy, treated patients saw a marked reduction in body fat. Biohaven plans to launch a Phase II trial in obesity by the end of the year.
November 25, 2024
·
2 min read
·
Tristan Manalac
Neurodegenerative disease
Biohaven Sets Stage for Comeback With Pivotal Study Results in Spinocerebellar Ataxia
The FDA previously refused to review Biohaven’s candidate in the indication due to a failed late-stage trial. However, the company is now planning to file an NDA in the fourth quarter of 2024.
September 24, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
March 4, 2025
·
32 min read
Drug Development
Biohaven’s Phase I Data for Lead Protein Degrader Disappoints Investors
Despite Biohaven’s bispecific protein degrader cutting autoantibody IgG levels by up to 37% in an early-stage study, investors saw it as “below the high bar” of 60%, according to William Blair analysts.
May 30, 2024
·
2 min read
·
Tristan Manalac
Government
Trump Tariffs Miss Pharma For Now, But Uncertainties Loom
Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”
April 3, 2025
·
2 min read
·
Tristan Manalac
Business
Five Biggest Drug Face-Offs in Pharma History
Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of rivalry that includes blockbuster drugs Keytruda, Humira and Eliquis.
April 9, 2025
·
9 min read
·
Tristan Manalac
Tariffs
Trump Tariff Pause Sparks Late-Day Rally for Pharma Stocks—But Not All
Pharma stocks went on a wild ride Wednesday amid whiplashing tariff threats from the U.S. president.
April 10, 2025
·
2 min read
·
Annalee Armstrong
1 of 33,342
Next
